1. Home
  2. ELDN vs ESGL Comparison

ELDN vs ESGL Comparison

Compare ELDN & ESGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • ESGL
  • Stock Information
  • Founded
  • ELDN 2004
  • ESGL 1999
  • Country
  • ELDN United States
  • ESGL Singapore
  • Employees
  • ELDN N/A
  • ESGL N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • ESGL
  • Sector
  • ELDN Health Care
  • ESGL
  • Exchange
  • ELDN Nasdaq
  • ESGL Nasdaq
  • Market Cap
  • ELDN 164.1M
  • ESGL 154.7M
  • IPO Year
  • ELDN N/A
  • ESGL N/A
  • Fundamental
  • Price
  • ELDN $3.50
  • ESGL $4.00
  • Analyst Decision
  • ELDN Strong Buy
  • ESGL
  • Analyst Count
  • ELDN 2
  • ESGL 0
  • Target Price
  • ELDN $12.50
  • ESGL N/A
  • AVG Volume (30 Days)
  • ELDN 1.4M
  • ESGL 18.6K
  • Earning Date
  • ELDN 11-11-2025
  • ESGL 09-23-2025
  • Dividend Yield
  • ELDN N/A
  • ESGL N/A
  • EPS Growth
  • ELDN N/A
  • ESGL N/A
  • EPS
  • ELDN 0.21
  • ESGL N/A
  • Revenue
  • ELDN N/A
  • ESGL $5,328,277.00
  • Revenue This Year
  • ELDN N/A
  • ESGL N/A
  • Revenue Next Year
  • ELDN N/A
  • ESGL N/A
  • P/E Ratio
  • ELDN $16.22
  • ESGL N/A
  • Revenue Growth
  • ELDN N/A
  • ESGL N/A
  • 52 Week Low
  • ELDN $2.32
  • ESGL $0.90
  • 52 Week High
  • ELDN $5.54
  • ESGL $4.32
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 70.99
  • ESGL 59.08
  • Support Level
  • ELDN $2.58
  • ESGL $3.56
  • Resistance Level
  • ELDN $2.71
  • ESGL $3.97
  • Average True Range (ATR)
  • ELDN 0.24
  • ESGL 0.22
  • MACD
  • ELDN 0.07
  • ESGL -0.03
  • Stochastic Oscillator
  • ELDN 72.69
  • ESGL 55.26

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About ESGL ESGL Holdings Limited

ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.

Share on Social Networks: